NCT06120075

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

This Phase 1/1b research study evaluates the safety, tolerability, and preliminary efficacy of AB801 as monotherapy and in combination therapy for participants with advanced malignancies. It aims to establish the safety profile, optimal dosing, and potential benefits of AB801 in treating various types of advanced cancers, addressing significant clinical needs in oncology. The trial includes participants with various types of advanced cancers. This broad inclusion criterion allows for a diverse assessment of AB801's effects across different cancer types.

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06120075

Clinical Trial Site: Sinai

To see all available clinical trials click here.